All News
VTE are LESS in RA using TNFi vs csDMARDs and other bDMARDs from German large RABBIT registry. No JAKi in this analysis. HOT TOPIC. Also may be true for Crohns @eular_org #EULAR2020goesvirtual #eular20 @RheumNow @CRASCRRheum opening plenary https://t.co/RQVbY4ztGt
Janet Pope Janetbirdope ( View Tweet)
RA pts are at risk of pneumonia, & inflamed lung mucosa can produce RF/CCP. Are these linked via subclinical lung injury?
Seropos RA pts @BrighamWomens have double the pneumonia risk post-adjustment.
We're still learning more about RF...
@jeffsparks OP0111 #EULAR2020 @RheumNow https://t.co/C3CYpXABGc
David Liew drdavidliew ( View Tweet)
GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail.
Large Israeli database says there are links
(EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why?
OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah
David Liew drdavidliew ( View Tweet)
AAV/PAN and cancer: risk from meds has always been the question.
Interesting therefore that GPA/MPA pts accumulated incident cancer risk over time, whereas other AAV/PAN pts had risk early after dx...
Jo Tieu 🇦🇺@earlyARA @helenkeen73 @CatherineL_Hill OP0145 #EULAR2020 @RheumNow https://t.co/8ywycZuMHV
David Liew drdavidliew ( View Tweet)
Tenosynovitis is underrated in RA.
A nice reminder from an Argentinian group, who USS scanned 90 RA pts in clinical remission >3m and followed them for 12m. Subclinical synovitis did not predict flares, but subclinical tenosynovitis did (adj OR 9.8)
THU0119 #EULAR2020 @RheumNow https://t.co/kcle8qyQbI
David Liew drdavidliew ( View Tweet)
Physician global assessment in RA is a murky beast, which we should standardise better (especially interrater).
Portuguese cross-sectional (n = 392): SJC/CRP/HAQ/PGA did not fully explain it.
What are we capturing, and does it matter?
THU0111 #EULAR2020 @Janetbirdope @RheumNow https://t.co/krL2yFIl8a
David Liew drdavidliew ( View Tweet)
Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing).
It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab!
@DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd
David Liew drdavidliew ( View Tweet)
JAKi and VTE from @WHO VigiBase @UMCGlobalSafety
Why the difference between Europe and US?
There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection
OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM
David Liew drdavidliew ( View Tweet)
RA isn't just a disease of joints & tendons: muscle is abnormal even at diagnosis. Changes throughout disease seen on MRI: T2, fatty infiltration, muscle volume all vary at different stages. Plenty more to understand/optimise! @LeedsBRC @DrAiLynTan OP0332 #EULAR2020 @RheumNow https://t.co/PwjLuZ1wcL https://t.co/QSYZALfi29
David Liew drdavidliew ( View Tweet)
I mean, the EULAR recommendations for management of early arthritis are tough:
"1. Patients presenting arthritis... should be referred to, and seen by, a rheumatologist, within 6 weeks after the onset of symptoms"
Does it matter though?
https://t.co/wJkVHQZqjs
David Liew drdavidliew ( View Tweet)
Outcome measures => Validity and reliability from @sofiaramiro82 #EULAR2020 @RheumNow https://t.co/M3XIDsTK39
Dr Philip Robinson philipcrobinson ( View Tweet)
MAINRITSAN3 RCT, RTX v PLBO in AAV
28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8)
1. Selected grp (all pts from MAINRITSAN2)
2. All pts had GC q3mos - IRL benefit could be bigger?
Strong data for RTX >2yrs in AAV
PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
Mike Putman EBRheum ( View Tweet)
Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N
Dr. John Cush RheumNow ( View Tweet)
Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The first randomized clinical trial of convalescent plasma in #COVID19, reported by Li et al in JAMA suggests that high titer antibody against #SARSCoV2 may have antiviral efficacy https://t.co/6YIib2GXGX
JAMA JAMA_current ( View Tweet)